MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Total Non-current Liabilities
All obligations due after more than one year.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Total Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026
Total non-current liabilities rises 426.1% from a year ago
Total non-current liabilities stood at $2.5M at the end of Q3 FY2026, up 426.1% from a year earlier and down 7.6% from the prior quarter. Over 3 fiscal years it compounded at -82.8% a year.
Context
- Total non-current liabilities amounted to 0.5% of total assets at the end of Q3 FY2026, up 0.4 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +426.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 426K USD
- Year-over-year change
- +914.3%
- 3-year CAGR
- -82.8%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 426K | +914.3% |
| FY2024 | 2024-12-31 | 42K | -100.0% |
| FY2023 | 2023-12-31 | 152.72M | +81.2% |
| FY2022 | 2022-12-31 | 84.27M | — |
Total Non-current Liabilities vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +426.1% is the 4th highest of 8, against a peer median of +182.6%.
- Total non-current liabilities amounts to 0.5% of total assets for MBX, versus a peer median of 13.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €377.65M EUR | +10.3% | +53.4% | 15.6% | |
| Mar 2026 | $260.41M USD | +1.9% | +4.9% | 66.4% | |
| Sep 2026 | $90.7M USD | -15.2% | +10.0% | 20.5% | |
| Mar 2026 | $40.32M USD | +660.3% | +106.0% | 12.0% | |
| Mar 2026 | $20.01M USD | +829.3% | +36.4% | 7.4% | |
| Mar 2026 | $18.37M USD | +182.6% | +120.7% | 39.6% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $9.3M USD | — | — | 0.8% |
| Jun 2026 | $3.93M USD | +857.3% | — | 0.8% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $2.5M USD | +426.1% | -82.8% | 0.5% |
| Peer median (excluding MBX) | — | +182.6% | +44.9% | 13.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.